更新于：2024-09-20

Celecoxib

塞来昔布

更新于：2024-09-20

概要

概要

基本信息

简介CELEBREX是一种非甾体抗炎药。Celecoxib具有镇痛，抗炎和退热作用。CELEBREX的作用机制被认为是通过抑制前列腺素合成，主要通过抑制COX-2而实现的。Celecoxib是体外前列腺素合成的强效抑制剂。治疗期间达到的Celecoxib浓度已经产生了体内效果。前列腺素使传入神经末梢变得敏感，并增强了缓激肽诱导动物模型疼痛的作用。前列腺素是炎症介质。由于Celecoxib是前列腺素合成的抑制剂，因此其作用机制可能是通过减少外周组织中的前列腺素而实现的。CELEBREX适用于骨关节炎（OA），类风湿性关节炎（RA），少年类风湿性关节炎（JRA），强直性脊柱炎（AS），急性疼痛，原发性痛经。它最初由辉瑞公司在1998年在美国上市，用于治疗关节炎。

药物类型

小分子化药

别名

Celecoxib (JAN/USP/INN)、p-(5-p-Tolyl-3-(trifluoromethyl)pyrazol-1-yl)benzenesulfonamide、AD-2111

+ [22]

靶点

COX-2

作用机制

COX-2抑制剂(环氧化酶-2抑制剂)

治疗领域

癌症免疫系统疾病感染+ [7]

在研适应症

偏头痛疼痛牙痛+ [18]

非在研适应症

光化性角化病食管腺癌前列腺腺癌+ [36]

原研机构

Pfizer Inc.

在研机构

Astellas Pharma, Inc.Viatris Pharmaceutical LLCUpjohn US 2 LLC

+ [6]

非在研机构

Pfizer Inc.

Viatris, Inc.

Pharmacia Corp.

+ [10]

最高研发阶段批准上市

首次获批日期

美国 (1998-12-31),

骨关节炎类风湿关节炎

最高研发阶段(中国)批准上市

特殊审评加速批准 (美国)、孤儿药 (美国)、优先审评 (中国)

登录后查看首次获批时间轴

结构

分子式C17H14F3N3O2S

InChIKeyRZEKVGVHFLEQIL-UHFFFAOYSA-N

CAS号169590-42-5

关联

699

项与塞来昔布相关的临床试验

IRCT20200306046708N1 / Suspended临床2/3期IIT

Celecoxib added to mood stabilizer for treating acute mania: A randomized, double-blind, placebo-controlled trial

开始日期2633-12-15

申办/合作机构

Mashhad University of Medical Sciences

NCT03590821 / Not yet recruiting早期临床1期IIT

Modulating Celecoxib Induced Blood Pressure Changes by Timed Administration of Aspirin and the Human Chronobiome

To determine whether timed administration of aspirin ameliorates the effects of celecoxib on blood pressure.

开始日期2026-12-01

申办/合作机构

University of Pennsylvania

NCT04860635 / Suspended临床2/3期

An Open Label Safety Study of a Single Administration of F14 in Patients Undergoing Unilateral Total Knee Replacement

Open-label single-arm study in which all subjects receive F14 as part of a scheduled TKR and multimodal analgesia

开始日期2025-01-01

申办/合作机构

Arthritis Innovation Corp.

100 项与塞来昔布相关的临床结果

登录后查看更多信息

100 项与塞来昔布相关的转化医学

登录后查看更多信息

100 项与塞来昔布相关的专利（医药）

登录后查看更多信息

7,296

项与塞来昔布相关的文献（医药）

2024-12-31·Journal of enzyme inhibition and medicinal chemistry

Discovery of new thymol-3,4-disubstituted thiazole hybrids as dual COX-2/5-LOX inhibitors with in vivo proof

Article

作者: El-Zemity, Saad R ; Al-Kubeisi, Ahmed K ; Nassra, Rasha A ; El-Miligy, Mostafa M M ; Hazzaa, Aly A

New thymol-3,4-disubstitutedthiazole hybrids were synthesised as dual COX-2/5-LOX inhibitors. Compounds 6b, 6d, 6e, and 6f displayed in vitro inhibitory activity against COX-2 (IC₅₀= 0.037, 0.042, 0.046, and 0.039 µM) nearly equal to celecoxib (IC₅₀= 0.045 µM). 6b, 6d, and 6f showed SI (379, 341, and 374, respectively) higher than that of celecoxib (327). 6a-l elicited in vitro 5-LOX inhibitory activity higher than quercetin. 6a-f, 6i-l, 7a, and 7c possessed in vivo inhibition of formalin induced paw edoema higher than celecoxib. 6a, 6b, 6f, 6h-l, and 7b showed gastrointestinal safety profile as celecoxib and diclofenac sodium in the population of fasted rats. Induced fit docking and molecular dynamics simulation predicted good fitting of 6b and 6f without changing the packing and globularity of the apo protein. In conclusion, 6b and 6f achieved the target goal as multitarget inhibitors of inflammation.

2024-06-15·Internal medicine (Tokyo, Japan)

Drug-induced Liver Injury Considered Steroid-resistant and Histologically Diagnosed with Vanishing Bile Duct Syndrome

Article

作者: Makazu, Makomo ; Koizumi, Kazuya ; Kako, Makoto ; Shionoya, Kento ; Kobayashi, Masahiro ; Masuda, Sakue

Vanishing bile duct syndrome (VBDS) is characterized by bile duct degeneration and necrosis, which result in bile duct loss and bile stasis. A 70-year-old man had malaise after receiving celecoxib. Laboratory tests revealed elevated hepatobiliary enzymes. His condition worsened without response to medical treatment, and he was transferred to our hospital. A liver biopsy revealed severe bile duct injury and mild cholestasis. He was diagnosed with celecoxib-induced VBDS and underwent bilirubin adsorption therapy. However, his condition continued to deteriorate, and he died. An autopsy showed that liver regeneration was poor, and bile duct loss was exacerbated. The pathological autopsy findings were consistent with VBDS.

2024-06-01·International journal of pharmaceutics: X

Repurposing celecoxib for colorectal cancer targeting via pH-triggered ultra-elastic nanovesicles: Pronounced efficacy through up-regulation of Wnt/β-catenin pathway in DMH-induced tumorigenesis

Article

作者: Shalaby, Khaled ; Abou Alazayem, Mahmoud A. ; Abdelmeged, Abdelmeged A. ; Ahmed, Yasmin M. ; Elkarmalawy, Marwa ; Elkomy, Mohammed H. ; Aboud, Heba M. ; El Menshawe, Shahira F. ; El Sisi, Amani M.

Celecoxib (CLX), a selective inhibitor for cyclooxygenase 2 (COX-2), has manifested potential activity against diverse types of cancer. However, low bioavailability and cardiovascular side effects remain the major challenges that limit its exploitation. In this work, we developed ultra-elastic nanovesicles (UENVs) with pH-triggered surface charge reversal traits that could efficiently deliver CLX to colorectal segments for snowballed tumor targeting. CLX-UENVs were fabricated via a thin-film hydration approach. The impact of formulation factors (Span 80, Tween 80, and sonication time) on the nanovesicular features was evaluated using Box-Behnken design, and the optimal formulation was computed. The optimum formulation was positively coated with polyethyleneimine (CLX-PEI-UENVs) and then coated with Eudragit S100 (CLX-ES-PEI-UENVs). The activity of the optimized nano-cargo was explored in 1,2-dimethylhydrazine-induced colorectal cancer in Wistar rats. Levels of COX-2, Wnt-2 and β-catenin were assessed in rats' colon. The diameter of the optimized CLX-ES-PEI-UENVs formulation was 253.62 nm, with a zeta potential of -23.24 mV, 85.64% entrapment, and 87.20% cumulative release (24 h). ES coating hindered the rapid release of CLX under acidic milieu (stomach and early small intestine) and showed extended release in the colon section. In colonic environments, the ES coating layer was removed due to high pH, and the charge on the nanovesicular corona was shifted from negative to positive. Besides, a pharmacokinetics study revealed that CLX-ES-PEI-UENVs had superior oral bioavailability by 2.13-fold compared with CLX suspension. Collectively, these findings implied that CLX-ES-PEI-UENVs could be a promising colorectal-targeted nanoplatform for effective tumor management through up-regulation of the Wnt/β-catenin pathway.

355

项与塞来昔布相关的新闻（医药）

2024-09-12

·GlobeNewswire-Health Care

Scilex Holding Company Announces It Has Received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®)

PALO ALTO, Calif., Sept. 12, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that it has received the Drug Distributor Accreditation from the National Association of Boards of Pharmacy® (NABP®). Scilex has satisfied all the drug distributor criteria set in place by the NABP. The NABP® is a 501(c)(3) nonprofit organization founded in 1904. Working with their members – the state boards of pharmacy – they help support patient and prescription drug safety, through examinations that assess pharmacist competency, pharmacist licensure transfer and verification services, and various pharmacy accreditation programs. For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on Semnur Pharmaceuticals, refer to www.semnurpharma.com For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXA™” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which Scilex has recently completed a Phase 2 trial in low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. Scilex Holding Company is headquartered in Palo Alto, California. Forward-Looking Statements This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s long-term objectives and commercialization plans, future opportunities for Scilex, Scilex’s future business strategies and Scilex’s current and prospective product candidates. Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: www.scilexholding.com SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark. ELYXYB® is a registered trademark owned by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2024 Scilex Holding Company All Rights Reserved.

快速通道上市批准临床3期临床2期引进/卖出

2024-09-12

·国家药品监督管理局

国家药监局公布药品说明书适老化及无障碍改革试点名单（第三批）

根据《国家药监局关于发布药品说明书适老化及无障碍改革试点工作方案的公告》（2023年第142号），省级药品监管部门和国家药监局药品审评中心报送了参与试点的药品上市许可持有人和药品名单（第三批），现予公布。序号药品名称上市许可持有人1利伐沙班片天津力生制药股份有限公司2缬沙坦氨氯地平片（I）天津力生制药股份有限公司3呋塞米片天津力生制药股份有限公司4氢氯噻嗪片天津力生制药股份有限公司5盐酸普萘洛尔片天津力生制药股份有限公司6复方丹参滴丸天士力医药集团股份有限公司7养血清脑丸天士力医药集团股份有限公司8养血清脑颗粒天士力医药集团股份有限公司9盐酸二甲双胍片津药达仁堂集团股份有限公司新新制药厂10安宫牛黄丸津药达仁堂集团股份有限公司达仁堂制药厂11牛黄清心丸（局方）津药达仁堂集团股份有限公司达仁堂制药厂12大活络丸津药达仁堂集团股份有限公司达仁堂制药厂13清宫寿桃丸津药达仁堂集团股份有限公司达仁堂制药厂14包醛氧淀粉散天津太平洋制药有限公司15阿莫西林胶囊天津太平洋制药有限公司16包醛氧淀粉胶囊天津太平洋制药有限公司17吲达帕胺缓释胶囊天津太平洋制药有限公司18诺氟沙星胶囊天津太平洋制药有限公司19补肾通淋颗粒天津太平洋制药有限公司20牛磺酸颗粒天津太平洋制药有限公司21银黄颗粒天津太平洋制药有限公司22甲硝唑片天津太平洋制药有限公司23阿昔洛韦片天津太平洋制药有限公司24氨咖甘片天津太平洋制药有限公司25二羟丙茶碱片天津太平洋制药有限公司26非普拉宗片天津太平洋制药有限公司27格列本脲片天津太平洋制药有限公司28尼群地平片天津太平洋制药有限公司29羧甲司坦片天津太平洋制药有限公司30硝苯地平片天津太平洋制药有限公司31硝酸异山梨酯片天津太平洋制药有限公司32盐酸二甲双胍片天津太平洋制药有限公司33扎来普隆片天津太平洋制药有限公司34吲达帕胺片天津太平洋制药有限公司35利巴韦林片天津太平洋制药有限公司36复方磺胺甲噁唑片天津太平洋制药有限公司37谷维素片天津太平洋制药有限公司38醋酸氟轻松乳膏天津太平洋制药有限公司39丁酸氢化可的松乳膏天津太平洋制药有限公司40哈西奈德乳膏天津太平洋制药有限公司41健儿消食口服液天津和治药业集团有限公司42麦味地黄口服液天津和治药业集团有限公司43清喉咽合剂天津和治药业集团有限公司44清热解毒口服液天津和治药业集团有限公司45生脉饮天津和治药业集团有限公司46小儿咳喘灵口服液天津和治药业集团有限公司47小儿退热口服液天津和治药业集团有限公司48川贝止嗽合剂天津和治药业集团有限公司49消食健胃片天津和治药业集团有限公司50活力源片天津和治药业集团有限公司51四季感冒片天津和治药业集团有限公司52穿黄清热胶囊天津和治药业集团有限公司53血府逐瘀软胶囊天津和治药业集团有限公司54盐酸氟桂利嗪胶囊石家庄市华新药业有限责任公司55诺氟沙星胶囊石家庄市华新药业有限责任公司56盐酸二甲双胍缓释片石家庄市华新药业有限责任公司57吲达帕胺片石家庄市华新药业有限责任公司58盐酸左氧氟沙星片石家庄市华新药业有限责任公司59盐酸左氧氟沙星胶囊石家庄市华新药业有限责任公司60缬沙坦氨氯地平片（I）石家庄市华新药业有限责任公司61阿奇霉素干混悬剂石家庄市华新药业有限责任公司62阿奇霉素片石家庄市华新药业有限责任公司63硝酸甘油片石家庄市华新药业有限责任公司64伏格列波糖片石家庄市华新药业有限责任公司65头孢克肟干混悬剂石家庄市华新药业有限责任公司66菖麻熄风片黑龙江省济仁药业有限公司67参鹿茶黑龙江省济仁药业有限公司68前列闭尔通栓黑龙江省济仁药业有限公司69痹痛宁胶囊黑龙江乌苏里江制药有限公司哈尔滨分公司70氯诺昔康片黑龙江乌苏里江制药有限公司哈尔滨分公司71人参五味子颗粒黑龙江乌苏里江制药有限公司哈尔滨分公司72益脑宁片黑龙江新医圣制药有限责任公司73刺五加片黑龙江新医圣制药有限责任公司74宁神灵颗粒黑龙江新医圣制药有限责任公司75复方苦木消炎胶囊黑龙江新医圣制药有限责任公司76盐酸凯普拉生片江苏柯菲平医药股份有限公司77瑞维鲁胺片江苏恒瑞医药股份有限公司78羟乙磺酸达尔西利片江苏恒瑞医药股份有限公司79番泻叶颗粒江苏艾迪药业股份有限公司80米氮平片华裕（无锡）制药有限公司81氨氯地平阿托伐他汀钙片昆山龙灯瑞迪制药有限公司82雷米普利片昆山龙灯瑞迪制药有限公司83尼麦角林片昆山龙灯瑞迪制药有限公司84云南白药膏云南白药集团无锡药业有限公司85云南白药创可贴云南白药集团无锡药业有限公司86盐酸氨基葡萄糖片江苏正大清江制药有限公司87厄贝沙坦氢氯噻嗪片江苏中治制药有限公司88阿哌沙班片南京正大天晴制药有限公司89芦比前列酮软胶囊南京正大天晴制药有限公司90奥美沙坦酯氨氯地平片江苏诺泰澳赛诺生物制药股份有限公司91噻托溴铵粉雾剂正大天晴药业集团股份有限公司92伏立康唑分散片扬子江药业集团南京海陵药业有限公司93左乙拉西坦片扬子江药业集团南京海陵药业有限公司94黄蜀葵花总黄酮口腔贴片杭州康恩贝制药有限公司95肾宝合剂浙江康恩贝中药有限公司96复方玄驹胶囊浙江施强制药有限公司97山海丹颗粒浙江施强制药有限公司98枸橼酸氢钾钠颗粒浙江施强制药有限公司99小儿咳喘灵口服液杭州华润老桐君药业有限公司100葡萄糖酸锌口服溶液杭州华润老桐君药业有限公司101百令胶囊杭州中美华东制药有限公司102泮托拉唑钠肠溶胶囊杭州中美华东制药有限公司103阿卡波糖片杭州中美华东制药有限公司104氨氯地平阿托伐他汀钙片瀚晖制药有限公司105海博麦布片浙江海正药业股份有限公司106盐酸多奈哌齐片浙江华海药业股份有限公司107草酸艾司西酞普兰片浙江华海药业股份有限公司108左乙拉西坦片浙江华海药业股份有限公司109奥氮平口崩片浙江华海药业股份有限公司110奥美沙坦酯氢氯噻嗪片浙江华海药业股份有限公司111阿立哌唑口崩片浙江华海药业股份有限公司112缬沙坦氢氯噻嗪片浙江华海药业股份有限公司113他达拉非片浙江华海药业股份有限公司114盐酸贝那普利片浙江华海药业股份有限公司115多巴丝肼片浙江华海药业股份有限公司116盐酸舍曲林片浙江华海药业股份有限公司117盐酸帕罗西汀片浙江华海药业股份有限公司118普瑞巴林胶囊浙江华海药业股份有限公司119赛洛多辛胶囊浙江华海药业股份有限公司120甲磺酸雷沙吉兰片浙江华海药业股份有限公司121福辛普利钠片浙江华海药业股份有限公司122利培酮片浙江华海药业股份有限公司123阿立哌唑片浙江华海药业股份有限公司124磷酸西格列汀片浙江华海药业股份有限公司125西格列汀二甲双胍片(II)浙江华海药业股份有限公司126硝苯地平控释片浙江华海药业股份有限公司127富马酸卢帕他定片浙江华海药业股份有限公司128维格列汀片浙江华海药业股份有限公司129恩格列净片浙江华海药业股份有限公司130托吡酯片浙江华海药业股份有限公司131沙库巴曲缬沙坦钠片浙江昂利康制药股份有限公司132头孢克洛颗粒浙江昂利康制药股份有限公司133盐酸左氧氟沙星片浙江昂利康制药股份有限公司134替格瑞洛片浙江昂利康制药股份有限公司135琥珀酸普芦卡必利片浙江昂利康制药股份有限公司136磷酸西格列汀片浙江昂利康制药股份有限公司137头孢氨苄胶囊浙江昂利康制药股份有限公司138聚卡波非钙片浙江昂利康制药股份有限公司139泊沙康唑肠溶片江西山香药业有限公司140甲苯磺酸索拉非尼片江西山香药业有限公司141醋酸阿比特龙片江西山香药业有限公司142艾司奥美拉唑镁肠溶片江西山香药业有限公司143盐酸坦索罗辛缓释胶囊江西山香药业有限公司144雷贝拉唑钠肠溶片江西山香药业有限公司145甲磺酸多沙唑嗪缓释片江西山香药业有限公司146甲磺酸仑伐替尼胶囊江西山香药业有限公司147马来酸阿法替尼片江西山香药业有限公司148哌柏西利胶囊江西山香药业有限公司149狗皮膏江西地康药业有限公司150海马万应膏江西地康药业有限公司151十全大补酒南昌恒湖药酒有限责任公司152人参药酒南昌恒湖药酒有限责任公司153枸杞药酒南昌恒湖药酒有限责任公司154周公百岁酒南昌恒湖药酒有限责任公司155史国公药酒南昌恒湖药酒有限责任公司156苯磺酸左氨氯地平片江西施美药业股份有限公司157辣椒风湿膏江西吉安三力制药有限公司158风茄平喘膏江西吉安三力制药有限公司159愈裂贴膏江西吉安三力制药有限公司160冻疮未溃膏江西吉安三力制药有限公司161伤疖膏江西吉安三力制药有限公司162曲安奈德新霉素贴膏江西吉安三力制药有限公司163恩替卡韦片江西制药有限责任公司164氟哌啶醇片江西制药有限责任公司165阿托伐他汀钙片江西制药有限责任公司166化积口服液江西诚志永丰药业有限责任公司167桔贝合剂江西诚志永丰药业有限责任公司168麻杏甘石合剂江西诚志永丰药业有限责任公司169鲜竹沥江西诚志永丰药业有限责任公司170生脉饮（党参方）江西诚志永丰药业有限责任公司171五子衍宗口服液江西诚志永丰药业有限责任公司172健儿清解液江西诚志永丰药业有限责任公司173肾宝合剂江西诚志永丰药业有限责任公司174清热解毒口服液江西诚志永丰药业有限责任公司175生脉饮江西诚志永丰药业有限责任公司176桂附地黄口服液江西诚志永丰药业有限责任公司177金钱通淋口服液江西诚志永丰药业有限责任公司178金果饮江西诚志永丰药业有限责任公司179麦味地黄口服液江西诚志永丰药业有限责任公司180杞菊地黄口服液江西诚志永丰药业有限责任公司181玉屏风口服液江西诚志永丰药业有限责任公司182四逆汤江西诚志永丰药业有限责任公司183小青龙合剂江西诚志永丰药业有限责任公司184他达拉非片南昌立健药业有限公司185枸橼酸西地那非片南昌立健药业有限公司186脑安滴丸安徽雷允上药业有限公司187脑安胶囊安徽雷允上药业有限公司188复方苁蓉益智胶囊安徽雷允上药业有限公司189再造生血胶囊安徽雷允上药业有限公司190再造生血片安徽雷允上药业有限公司191益气养血口服液安徽雷允上药业有限公司192黄厚止泻滴丸安徽雷允上药业有限公司193卡马西平片宜昌人福药业有限责任公司194维生素B2片宜昌人福药业有限责任公司195维生素B6片宜昌人福药业有限责任公司196非布司他片宜昌人福药业有限责任公司197琥珀酸美托洛尔缓释片宜昌人福药业有限责任公司198盐酸二甲双胍缓释片宜昌人福药业有限责任公司199萘普生钠片宜昌人福药业有限责任公司200枸橼酸托法替布缓释片宜昌人福药业有限责任公司201氨酚羟考酮片宜昌人福药业有限责任公司202盐酸羟考酮缓释片宜昌人福药业有限责任公司203奥卡西平片武汉人福药业有限责任公司204安立生坦片武汉人福药业有限责任公司205ω-3脂肪酸乙酯90软胶囊人福普克药业（武汉）有限公司206布洛芬软胶囊人福普克药业（武汉）有限公司207度他雄胺软胶囊人福普克药业（武汉）有限公司208艾地骨化醇软胶囊人福普克药业（武汉）有限公司209乙磺酸尼达尼布软胶囊人福普克药业（武汉）有限公司210甲硝唑片远大医药（中国）有限公司211他达拉非片远大医药（中国）有限公司212酒石酸美托洛尔片远大医药（中国）有限公司213磷酸奥司他韦颗粒宜昌东阳光长江药业股份有限公司214磷酸奥司他韦胶囊宜昌东阳光长江药业股份有限公司215替米沙坦片宜昌东阳光长江药业股份有限公司216替格瑞洛片宜昌东阳光长江药业股份有限公司217非布司他片宜昌东阳光长江药业股份有限公司218氟康唑胶囊宜昌东阳光长江药业股份有限公司219西格列汀二甲双胍片II宜昌东阳光长江药业股份有限公司220西格列汀二甲双胍片Ⅲ宜昌东阳光长江药业股份有限公司221磷酸奥司他韦干混悬剂宜昌东阳光长江药业股份有限公司222克拉霉素片宜昌东阳光长江药业股份有限公司223苯甲酸阿格列汀片宜昌东阳光长江药业股份有限公司224琥珀酸索利那新片宜昌东阳光长江药业股份有限公司225阿哌沙班片宜昌东阳光长江药业股份有限公司226七蕊胃舒胶囊健民药业集团股份有限公司227虚汗停糖浆健民药业集团股份有限公司228小儿紫贝宣肺糖浆健民药业集团股份有限公司229盐酸托莫西汀口服溶液健民药业集团股份有限公司230拉考沙胺口服溶液健民药业集团股份有限公司231硫酸特布他林健民药业集团股份有限公司232马来酸噻吗洛尔滴眼液武汉新瑞医药科技有限公司233溴芬酸钠滴眼液武汉五景药业有限公司234阿莫西林胶囊湖南科伦制药有限公司235康复新液湖南科伦制药有限公司236泊沙康唑口服混悬液湖南科伦制药有限公司237血塞通片湖南绅泰春制药股份有限公司238六味地黄丸（浓缩丸）九芝堂股份有限公司239杞菊地黄丸（浓缩丸）九芝堂股份有限公司240驴胶补血颗粒九芝堂股份有限公司241蒙脱石散江右制药（常德）有限公司242复方金银花颗粒江右制药（常德）有限公司243风热感冒颗粒江右制药（常德）有限公司244前列癃闭通片江右制药（常德）有限公司245复方雪莲烧伤膏江右制药（常德）有限公司246四消丸江右制药（常德）有限公司247阿胶山东喜君康医药集团湘潭有限公司248苯磺酸氨氯地平片湖南千金协力药业有限公司249恩替卡韦分散片湖南千金协力药业有限公司250硫酸氨基葡萄糖胶囊湖南先施制药有限公司251古汉养生精口服液古汉中药有限公司252古汉养生精片古汉中药有限公司253枸橼酸西地那非片广州朗圣药业有限公司254他达拉非片广州朗圣药业有限公司255双氯芬酸钠缓释片国药集团致君（深圳）坪山制药有限公司256奥美沙坦酯氨氯地平片国药集团致君（深圳）坪山制药有限公司257依托考昔片国药集团致君（深圳）制药有限公司258左乙拉西坦片深圳信立泰药业股份有限公司259左乙拉西坦缓释片深圳信立泰药业股份有限公司260艾司奥美拉唑镁肠溶胶囊广东东阳光药业股份有限公司261奥氮平口崩片广东东阳光药业股份有限公司262富马酸喹硫平片广东东阳光药业股份有限公司263奥美沙坦酯片东莞市阳之康医药有限责任公司264盐酸莫西沙星片东莞市阳之康医药有限责任公司265阿立哌唑口崩片东莞市阳之康医药有限责任公司266阿立哌唑片东莞市阳之康医药有限责任公司267草酸艾司西酞普兰片东莞市阳之康医药有限责任公司268盐酸度洛西汀肠溶胶囊东莞市阳之康医药有限责任公司269厄贝沙坦胶囊珠海润都制药股份有限公司270厄贝沙坦氢氯噻嗪片珠海润都制药股份有限公司271复方丹参片广州白云山和记黄埔中药有限公司272脑栓通胶囊广东华南药业集团有限公司273盐酸安非他酮缓释片万特制药（海南）有限公司274阿立哌唑口服溶液万特制药（海南）有限公司275盐酸莫西沙星片重庆华邦制药有限公司276利伐沙班片重庆华邦制药有限公司277苯磺贝他斯汀片重庆华邦制药有限公司278萘替芬酮康唑乳膏重庆华邦制药有限公司279维A酸乳膏重庆华邦制药有限公司280盐酸左西替利嗪口服溶液重庆华邦制药有限公司281盐酸左西替利嗪片重庆华邦制药有限公司282阿伐斯汀胶囊重庆华邦制药有限公司283阿维A胶囊重庆华邦胜凯制药有限公司284异维A酸软胶囊重庆华邦胜凯制药有限公司285地奈德乳膏重庆华邦胜凯制药有限公司286甘桔冰梅片重庆华森制药股份有限公司287痛泻宁颗粒重庆华森制药股份有限公司288都梁软胶囊重庆华森制药股份有限公司289八味芪龙颗粒重庆华森制药股份有限公司290铝碳酸镁片重庆华森制药股份有限公司291铝碳酸镁咀嚼片重庆华森制药股份有限公司292奥美拉唑碳酸氢钠胶囊重庆华森制药股份有限公司293奥美沙坦酯氨氯地平片重庆华森制药股份有限公司294小金片太极集团重庆桐君阁药厂有限公司295苏合香丸太极集团重庆桐君阁药厂有限公司296沉香化气片太极集团重庆桐君阁药厂有限公司297强力天麻杜仲丸太极集团重庆桐君阁药厂有限公司298麻仁丸太极集团重庆桐君阁药厂有限公司299安宫牛黄丸太极集团重庆桐君阁药厂有限公司300还少丹（大蜜丸）太极集团重庆桐君阁药厂有限公司301还少丹太极集团重庆桐君阁药厂有限公司302归脾合剂太极集团重庆桐君阁药厂有限公司303桔贝合剂太极集团重庆桐君阁药厂有限公司304拨云退翳丸太极集团重庆桐君阁药厂有限公司305藿香正气口服液太极集团重庆涪陵制药厂有限公司306通天口服液太极集团重庆涪陵制药厂有限公司307急支糖浆太极集团重庆涪陵制药厂有限公司308急支颗粒太极集团重庆涪陵制药厂有限公司309补肾益寿胶囊太极集团重庆涪陵制药厂有限公司310丹参口服液太极集团重庆涪陵制药厂有限公司311盐酸文拉法辛片重庆药友制药有限责任公司312吲达帕胺片重庆药友制药有限责任公司313复方对乙酰氨基酚片（II）西南药业股份有限公司314布洛芬缓释片西南药业股份有限公司315维生素C咀嚼片西南药业股份有限公司316左氧氟沙星片四川新斯顿制药股份有限公司317塞来昔布胶囊四川新斯顿制药股份有限公司318盐酸氨基葡萄糖片四川新斯顿制药股份有限公司319苯酰甲硝唑分散片四川新斯顿制药股份有限公司320氯雷他定口腔崩解片四川新斯顿制药股份有限公司321盐酸美金刚片四川新斯顿制药股份有限公司322左氧氟沙星滴眼液四川美大康华康药业有限公司323盐酸莫西沙星滴眼液四川美大康华康药业有限公司324伏立康唑片四川美大康华康药业有限公司325来那度胺胶囊四川美大康华康药业有限公司326普乐安片云南白药集团股份有限公司327藿香正气胶囊云南白药集团股份有限公司328复方丹参片云南白药集团股份有限公司329六味地黄胶囊云南白药集团股份有限公司330关节止痛膏云南白药集团股份有限公司331伤湿止痛膏云南白药集团股份有限公司332麝香跌打风湿膏云南白药集团股份有限公司333一枝蒿伤湿祛痛膏云南白药集团股份有限公司334参苓健脾胃颗粒云南白药集团股份有限公司335宫血宁胶囊云南白药集团股份有限公司336痛舒胶囊云南白药集团股份有限公司337三七参蜂口服液云南白药集团股份有限公司338伤风停胶囊云南白药集团股份有限公司339丹溪玉屏风颗粒云南白药集团股份有限公司340风热感冒颗粒云南白药集团股份有限公司341四季感冒片云南白药集团股份有限公司342妇炎康片云南白药集团股份有限公司343痛舒片云南白药集团股份有限公司344消炎退热颗粒云南白药集团股份有限公司345板蓝根颗粒云南白药集团股份有限公司346热毒清片云南白药集团股份有限公司347玄麦甘桔颗粒云南白药集团股份有限公司348天紫红女金胶囊云南白药集团股份有限公司349小儿健脾平肝颗粒云南白药集团股份有限公司350小儿七星茶颗粒云南白药集团股份有限公司351止泻保童颗粒云南白药集团股份有限公司352泻痢消胶囊云南白药集团股份有限公司353生脉饮（党参方）云南白药集团股份有限公司354肿痛气雾剂云南白药集团股份有限公司355伤益气雾剂云南白药集团股份有限公司356利儿康口服液云南白药集团股份有限公司357陈香露白露片云南白药集团大理药业有限责任公司358气血康口服液云南白药集团文山七花有限责任公司359血塞通软胶囊昆药集团股份有限公司360血塞通片云南维和药业股份有限公司361血塞通胶囊云南维和药业股份有限公司362血塞通颗粒云南维和药业股份有限公司363盐酸莫西沙星片Bayer Vital GmbH364屈螺酮炔雌醇片Bayer Australia Ltd365琥珀酸索利那新片Astellas Pharma Europe B.V.366盐酸普拉克索片Boehringer Ingelheim International GmbH367达比加群酯胶囊Boehringer Ingelheim International GmbH368盐酸普拉克索缓释片Boehringer Ingelheim International GmbH369马来酸阿法替尼片Boehringer Ingelheim International GmbH

2024-09-09

·GlobeNewswire-Health Care

Scilex Holding Company to Present at the 26th Annual H.C. Wainwright Global Investment Conference

PALO ALTO, Calif., Sept. 09, 2024 (GLOBE NEWSWIRE) -- Scilex Holding Company (Nasdaq: SCLX, “Scilex” or “Company”), an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain, today announced that Jaisim Shah, Chief Executive Officer and President of Scilex will present at the 26th Annual H.C. Wainwright Global Investment Conference taking place September 9-11, 2024 in New York City. Details on the presentation: H.C. Wainwright 26th Annual Global Investment Conference Location: Lotte NY Palace Hotel, New York CityDate: September 11, 2024Time: 8-8:30am ET For more information on Scilex Holding Company, refer to www.scilexholding.com For more information on Scilex Holding Company Sustainability Report, refer to www.scilexholding.com/investors/sustainability For more information on ZTlido® including Full Prescribing Information, refer to www.ztlido.com. For more information on ELYXYB®, including Full Prescribing Information, refer to www.elyxyb.com. For more information on Gloperba®, including Full Prescribing Information, refer to www.gloperba.com. https://www.facebook.com/scilex.pharm https://www.linkedin.com/company/scilex-holding-company/ info@scilexholding.com About Scilex Holding Company Scilex Holding Company is an innovative revenue-generating company focused on acquiring, developing and commercializing non-opioid pain management products for the treatment of acute and chronic pain. Scilex targets indications with high unmet needs and large market opportunities with non-opioid therapies for the treatment of patients with acute and chronic pain and is dedicated to advancing and improving patient outcomes. Scilex’s commercial products include: (i) ZTlido® (lidocaine topical system) 1.8%, a prescription lidocaine topical product approved by the U.S. Food and Drug Administration (the “FDA”) for the relief of neuropathic pain associated with postherpetic neuralgia, which is a form of post-shingles nerve pain; (ii) ELYXYB®, a potential first-line treatment and the only FDA-approved, ready-to-use oral solution for the acute treatment of migraine, with or without aura, in adults; and (iii) Gloperba®, the first and only liquid oral version of the anti-gout medicine colchicine indicated for the prophylaxis of painful gout flares in adults. In addition, Scilex has three product candidates: (i) SP-102 (10 mg, dexamethasone sodium phosphate viscous gel) (“SEMDEXATM” or “SP-102”), a novel, viscous gel formulation of a widely used corticosteroid for epidural injections to treat lumbosacral radicular pain, or sciatica, for which Scilex has completed a Phase 3 study and was granted Fast Track status from the FDA in 2017; (ii) SP-103 (lidocaine topical system) 5.4%, (“SP-103”), a next-generation, triple-strength formulation of ZTlido, for the treatment of chronic neck pain and for which Scilex has recently completed a Phase 2 trial in low back pain. SP-103 has been granted Fast Track status from the FDA in low back pain; and (iii) SP-104 (4.5 mg, low-dose naltrexone hydrochloride delayed-release capsules) (“SP-104”), a novel low-dose delayed-release naltrexone hydrochloride being developed for the treatment of fibromyalgia, for which Phase 1 trials were completed in the second quarter of 2022. Scilex Holding Company is headquartered in Palo Alto, California. Forward-Looking Statements This press release and any statements made for and during any presentation or meeting concerning the matters discussed in this press release contain forward-looking statements related to Scilex and its subsidiaries under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995 and are subject to risks and uncertainties that could cause actual results to differ materially from those projected. Forward-looking statements include statements regarding Scilex’s long-term objectives and commercialization plans, future opportunities for Scilex, Scilex’s future business strategies and Scilex’s current and prospective product candidates. Risks and uncertainties that could cause Scilex’s actual results to differ materially and adversely from those expressed in our forward-looking statements, include, but are not limited to: risks associated with the unpredictability of trading markets; general economic, political and business conditions; the risk that the potential product candidates that Scilex develops may not progress through clinical development or receive required regulatory approvals within expected timelines or at all; risks relating to uncertainty regarding the regulatory pathway for Scilex’s product candidates; the risk that Scilex will be unable to successfully market or gain market acceptance of its product candidates; the risk that Scilex’s product candidates may not be beneficial to patients or successfully commercialized; the risk that Scilex has overestimated the size of the target patient population, their willingness to try new therapies and the willingness of physicians to prescribe these therapies; risks that the outcome of the trials and studies for SP-102, SP-103 or SP-104 may not be successful or reflect positive outcomes; risks that the prior results of the clinical and investigator-initiated trials of SP-102 (SEMDEXA™), SP-103 or SP-104 may not be replicated; regulatory and intellectual property risks; and other risks and uncertainties indicated from time to time and other risks described in Scilex’s most recent periodic reports filed with the Securities and Exchange Commission, including Scilex’s Annual Report on Form 10-K for the year ended December 31, 2023 and subsequent Quarterly Reports on Form 10-Q that the Company has filed or may file, including the risk factors set forth in those filings. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this release, and Scilex undertakes no obligation to update any forward-looking statement in this press release except as may be required by law. Contacts: Investors and MediaScilex Holding Company 960 San Antonio RoadPalo Alto, CA 94303Office: (650) 516-4310 Email: investorrelations@scilexholding.com Website: www.scilexholding.com SEMDEXA™ (SP-102) is a trademark owned by Semnur Pharmaceuticals, Inc., a wholly-owned subsidiary of Scilex Holding Company. A proprietary name review by the FDA is planned. ZTlido® is a registered trademark owned by Scilex Pharmaceuticals Inc., a wholly-owned subsidiary of Scilex Holding Company. Gloperba® is the subject of an exclusive, transferable license to Scilex Holding Company to use the registered trademark. ELYXYB® is a registered trademark owned by Scilex Holding Company. All other trademarks are the property of their respective owners. © 2024 Scilex Holding Company All Rights Reserved.

临床1期快速通道临床3期上市批准引进/卖出

100 项与塞来昔布相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
D00567	塞来昔布	L01XX33 M01AH01	DB00482

研发状态

批准上市

10 条最早获批的记录,

后查看更多信息

适应症	国家/地区	公司	日期
偏头痛	美国	Scilex Pharmaceuticals, Inc.	2020-05-05
疼痛	日本	Astellas Pharma, Inc.	2011-12-22
牙痛	日本	Viatris Pharmaceutical LLC	2011-12-22
滑囊炎	日本	Viatris Pharmaceutical LLC	2009-06-17
颈臂综合征	日本	Astellas Pharma, Inc.	2009-06-17
颈臂综合征	日本	Viatris Pharmaceutical LLC	2009-06-17
腰痛	日本	Astellas Pharma, Inc.	2009-06-17
腰痛	日本	Viatris Pharmaceutical LLC	2009-06-17
关节周围炎	日本	Astellas Pharma, Inc.	2009-06-17
肌腱病	日本	Astellas Pharma, Inc.	2009-06-17
肌腱病	日本	Viatris Pharmaceutical LLC	2009-06-17
腱鞘炎	日本	Viatris Pharmaceutical LLC	2009-06-17
镇痛	日本	Viatris Pharmaceutical LLC	2007-01-26
炎症	日本	Viatris Pharmaceutical LLC	2007-01-26
幼年特发性关节炎	美国	Upjohn US 2 LLC	2006-12-15
原发性痛经	美国	Upjohn US 2 LLC	2001-10-18
急性疼痛	中国	Viatris Pharmaceuticals LLC	2000-08-01
AS	中国	Viatris Pharmaceuticals LLC	2000-08-01
腺瘤性结肠息肉病	美国	Viatris Holdings LLC	1999-12-23
骨关节炎	美国	Upjohn US 2 LLC	1998-12-31

未上市

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
无先兆偏头痛	申请上市	加拿大	Scilex Holding Co.	2023-12-26
光化性角化病	临床3期	美国	Dr. Reddy's Laboratories Ltd. (Russia)	2017-02-14
痛风性关节炎	临床3期	美国	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	加拿大	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥伦比亚	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	哥斯达黎加	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	墨西哥	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	秘鲁	Viatris, Inc.	2008-02-01
痛风性关节炎	临床3期	菲律宾	Viatris, Inc.	2008-02-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT03859024 (CTgov)	临床4期	尿道狭窄 \| 术后疼痛	48	Acetaminophen+Ibuprofen 800 mg+Oxycodone (Standard Protocol)	鏇夢網蓋壓製顧獵繭網(獵範鏇蓋遞衊膚餘壓齋) = 壓醖網鹹遞窪憲壓醖積顧遞糧願獵鑰觸顧壓糧 (鹽糧鏇繭膚壓廠齋鬱鑰, 顧遞築鬱鏇鑰艱選鏇範 ~ 糧獵醖廠簾壓願願艱鹽) 更多	-	2024-09-19
				Acetaminophen+Ibuprofen 800 mg+celebrex+Dexamethasone+Oxycodone+Bupivacaine+Gabapentin (Enhanced Recovery Protocol)	鏇夢網蓋壓製顧獵繭網(獵範鏇蓋遞衊膚餘壓齋) = 膚艱蓋築觸築憲鏇範範顧遞糧願獵鑰觸顧壓糧 (鹽糧鏇繭膚壓廠齋鬱鑰, 廠網簾鏇廠構網糧膚餘 ~ 憲鏇醖築醖鬱鑰獵襯鏇) 更多
NCT05077969 (CTgov)	临床2期	SARS-CoV-2 急性呼吸道疾病	4	Famotidine+Celecoxib (Group 1 (Study Product))	淵獵積憲鹽鏇壓鹽構構(鏇網觸鑰積餘範網積餘) = 築壓積襯繭築淵醖膚夢顧糧獵壓蓋構選糧築積 (醖積繭餘窪膚遞繭築選, 願鹹醖糧獵鹹艱製製遞 ~ 鹹鹽網積製襯鏇窪獵繭) 更多	-	2024-07-09
				Placebo (Group 2 (Reference Therapy))	淵獵積憲鹽鏇壓鹽構構(鏇網觸鑰積餘範網積餘) = 顧壓範製窪遞糧遞顧餘顧糧獵壓蓋構選糧築積 (醖積繭餘窪膚遞繭築選, 觸淵觸鑰繭窪餘窪艱壓 ~ 夢觸憲願鑰鑰夢觸網繭) 更多
NCT04015908 (CTgov)	临床4期	-	100	Pregabalin+Acetaminophen+Celecoxib+Oxycodone (Multi-modal)	廠選積鹽網遞製觸齋選(築顧製齋襯網簾淵獵憲) = 網壓積鬱淵願獵繭鑰築襯獵餘獵鏇繭淵鏇遞醖 (獵夢蓋淵夢醖壓鏇願齋, 蓋夢齋築夢觸壓壓窪積 ~ 鬱遞醖窪顧顧觸憲遞鹽) 更多	-	2024-07-08
				Percocet (Control)	廠選積鹽網遞製觸齋選(築顧製齋襯網簾淵獵憲) = 鑰壓簾醖淵構鏇遞獵顧襯獵餘獵鏇繭淵鏇遞醖 (獵夢蓋淵夢醖壓鏇願齋, 製艱壓積繭簾築遞製膚 ~ 遞鏇鏇鹽遞膚網鏇網願) 更多
NCT05062083 (CTgov)	临床2期	多发性硬化症	7	11C-PS13+11C-MC1+Celecoxib+ketoprofen	顧範簾憲壓壓窪糧襯範(襯選醖憲築製淵顧築築) = 網醖壓築醖願夢鬱製範醖夢觸襯範夢艱鬱獵選 (鏇衊衊齋鹽願遞願鹹築, 鹹鏇窪蓋襯遞鬱鑰糧製 ~ 遞膚願衊淵衊餘憲膚繭) 更多	-	2024-06-27
NCT03006276 \| NCT03009019 (GlobeNewswire) 人工标引	临床3期	偏头痛	-	ELYXYB (Triptan Insufficient Responders)	憲製構遞選糧積顧襯製(鹹願壓艱願膚繭餘積鹽) = 壓範鹽膚遞衊鏇鹹糧製構構顧膚構願範醖壓齋 (鬱鹹壓簾構製襯遞鏇醖 )	积极	2024-06-13
				placebo (Triptan Insufficient Responders)	憲製構遞選糧積顧襯製(鹹願壓艱願膚繭餘積鹽) = 廠鹽窪範餘鏇膚艱鹽範構構顧膚構願範醖壓齋 (鬱鹹壓簾構製襯遞鏇醖 )
NCT01479829 (CTgov)	临床4期	抑郁症 \| 炎症	100	Escitalopram+Celecoxib (Intervention Cohort)	鑰糧獵廠願壓膚獵獵齋(獵廠膚衊壓繭鹹淵蓋醖): Chi-square value = 5.3466, P-Value = 0.02 更多	-	2024-04-09
				Placebo+Escitalopram (Control Cohort)
NCT03818919 (CTgov)	临床2期	镇痛 \| 肩袖撕裂关节病	70	Acetaminophen+Diazepam+Ketorolac+Celecoxib+Gabapentin (Post-Operative Non Opioid Pain Protocol)	蓋夢醖範鹽鬱膚範觸遞(憲鬱選獵餘窪壓壓獵選) = 艱襯鹹廠製憲網醖窪糧鬱網積選繭願膚鬱選艱 (範窪淵顧顧淵願憲窪齋, 獵繭積鏇鹹夢觸顧觸夢 ~ 獵簾範選夢窪糧積壓鬱) 更多	-	2024-04-02
				Hydrocodone-Acetaminophen (Post-Operative Traditional Pain Protocol)	蓋夢醖範鹽鬱膚範觸遞(憲鬱選獵餘窪壓壓獵選) = 遞繭蓋窪膚鹽繭衊顧廠鬱網積選繭願膚鬱選艱 (範窪淵顧顧淵願憲窪齋, 築顧鹽憲築製遞膚範醖 ~ 廠壓鹹憲觸齋顧鹽蓋顧) 更多
NCT04790812 (CTgov)	临床4期	牙痛 \| 术后疼痛	65	Placebo+Celecoxib (Celecoxib Plus Placebo)	壓齋淵醖鏇憲鏇襯窪鑰(壓廠齋壓醖鬱獵糧遞鬱) = 網醖範鏇廠鑰襯襯衊醖膚憲糧觸遞鏇選膚獵願 (築範糧齋製壓蓋製衊齋, 遞膚簾廠簾鹹糧鏇遞製 ~ 網範觸製鬱觸鬱積衊繭) 更多	-	2024-03-27
				Acetaminophen+Celecoxib (Celecoxib Plus Acetaminophen)	壓齋淵醖鏇憲鏇襯窪鑰(壓廠齋壓醖鬱獵糧遞鬱) = 範顧選淵膚廠選夢繭網膚憲糧觸遞鏇選膚獵願 (築範糧齋製壓蓋製衊齋, 製鏇齋構襯廠艱遞築蓋 ~ 願鹹積鏇簾構壓淵壓構) 更多
NCT02502006 (CTgov)	临床1期	-	16	Celecoxib (Celecoxib)	願夢憲鏇蓋鑰衊鬱鑰膚(簾蓋遞鹽顧遞蓋觸窪鹽) = 淵顧鹽襯遞積範艱夢餘積窪遞構遞構襯鑰衊鬱 (構範餘齋顧鏇餘範淵網, 襯艱願鬱醖構鏇觸衊鏇 ~ 鬱選鬱艱鏇遞齋鬱獵醖) 更多	-	2023-12-13
				Naproxen (Naproxen)	願夢憲鏇蓋鑰衊鬱鑰膚(簾蓋遞鹽顧遞蓋觸窪鹽) = 餘餘鹹膚築憲壓廠鹽遞積窪遞構遞構襯鑰衊鬱 (構範餘齋顧鏇餘範淵網, 遞膚獵選淵遞獵築積積 ~ 顧願餘範醖獵壓膚憲獵) 更多
NCT04081389 (CTgov)	临床1期	三阴性乳腺癌 \| 早期乳腺癌	9	Interferon Alpha-2b (Arm 1: Interferon Alpha-2b at DL 1)	顧構艱鑰糧製壓窪繭餘(糧壓積顧膚築範積鬱憲) = 夢構製蓋築鬱憲構鏇夢齋艱餘憲鑰鬱顧網憲壓 (網鹽鑰衊窪壓餘齋餘顧, 選廠鬱積積顧衊遞襯蓋 ~ 繭醖範夢膚鬱構鹽築顧) 更多	-	2023-09-11
				Interferon Alpha-2b (Arm 2: Interferon Alpha-2b at DL 2)	顧構艱鑰糧製壓窪繭餘(糧壓積顧膚築範積鬱憲) = 製糧鑰願廠繭願蓋選憲齋艱餘憲鑰鬱顧網憲壓 (網鹽鑰衊窪壓餘齋餘顧, 鹽膚製壓鑰製積壓壓憲 ~ 選積壓鬱觸衊艱襯衊淵) 更多